- To see the full Biotech submenu, roll down and check out the menu bar on the left side of the screen. -

 

 

”It is worth investing in Hungary since, in the very recent years, Hungarian researchers have discovered two original molecules which are in development phase now.” Jean-François Dehecq –CEO, Sanofi-Aventis

 

In 2006, Sanofi-Aventis SA opened a EUR 15 million development laboratory and prototype factory at its Hungarian subsidiary Chinoin. Sanofi-Aventis already has an R&D center for internal medicine in Hungary, which has been involved in 50 development projects since 1996, including initial research and clinical testing. Since Chinoin's privatization in 1991, the owners have invested a combined EUR 500 million in the company. In 2005, Chinoin completed a HUF 3.4 billion project at its plant in northeast Hungary to double production capacity for ampoules and injections, and spent a further HUF 11.2 billion at its plant outside of Budapest to double production capacity of pills. Sanofi-Aventis now employs over 2,400 people in Hungary.

 

”In our world, safety and confidence in our products are essential. TEVA is one of the world leaders in the generic pharmaceutical industry. Our European manufacturing center is located in Hungary. At TEVA, as in Hungary, maintaining good health is our primary

goal.” András Rózsa // TEVA Hungary CEO

 

TEVA Hungary is to build a EUR 75 million factory for the production of active pharmaceutical ingredients (APIs) in Sajóbábony, Hungary. 60–100 people will be employed at the facility, and its products will be mostly exported. TEVA started manufacturing in Hungary in 1995 and now employs 2,400 people in the country.

 

“The former Human pharmaceutical plant has the tradition and technology of human vaccines production. We have taken the opportunity to buy this plant with a strong belief that we can build on the quality of local workforce on the long term.”

Andrew Witty // GSK Pharmaceuticals, European President

 

In 2006 September, GSK inaugurated a EUR 100 million vaccine production plant in Gödöllő, a Hungarian city 30 km northeast of Budapest. The new site is one of Europe's most advanced biotechnology plants and will manufacture two types of vaccines, one of which is DPT, a combination of three vaccines to immunise against diphtheria, pertussis and tetanus. The drug maker plans output in the order of 100 million units a year to cover its entire worldwide demand. The new vaccine plant started production in January 2007 and employs over 200 people.

 

Should you be interested in cooperating with biotech companies, visit this site for a detailed list of ongoing biotech projects.